Status of work on December

AOTMiT begins work on the Ministry of Health’s orders in December:

• Ocrevus, ocrelizumab for the treatment of multiple sclerosis,
• Vyepti, eptinezumab for the treatment of chronic migraine,
• Rubraca, rucaparib in the treatment of ovarian cancer,
• Ebglyss, lebrikizumab for the treatment of atopic dermatitis.

The listed orders are available on AOTMiT’s Public Information Bulletin – click here.